Ilya Pharma’s ILP100 Phase I wound care therapy trial progresses swiftly to multiple dosing
Ilya Pharma, a clinical stage biopharma company, today announced that multiple dosing in the Phase I trial for its lead candidate ILP100 has already commenced. Initial single dosing in three cohorts has been completed in 4 months which represents rapid progress. ILP100 is the first drug based on genetically engineered lactic acid bacteria to be approved to enter trials as a topical treatment. The Company is now preparing for the phase II clinical developments and in response, Ilya has strengthened its clinical development team with two key senior appointments with key experience: ex-Renovo / Smith & Nephew Wound Management David Fairlamb as expert advisor and ex Novartis Andreas Fasth as Head of Clinical Developments.